Methods of detecting circulating cell-free HPV 6 and HPV 11 DNA in liquid biopsies
A hybridization-based NGS panel targeting HPV 6 and HPV 11 genomes in liquid biopsies addresses the limitations of current detection methods by providing sensitive and specific HPV DNA detection, enabling effective monitoring and treatment guidance for conditions like recurrent respiratory papillomatosis.
Patent Information
- Application Number
- PCT/US2026/027273
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current methods for detecting HPV 6 and HPV 11 DNA in liquid biopsies, particularly for conditions like recurrent respiratory papillomatosis, are limited in sensitivity and specificity, failing to reliably distinguish between HPV DNA from infected cells and intact virions, and are inadequate for monitoring disease progression and response to treatments.
A hybridization-based next-generation sequencing (NGS) panel is employed, targeting specific regions of the HPV 6 and HPV 11 genomes, allowing for comprehensive detection of HPV DNA fragments from infected cells in liquid biopsies, such as peripheral blood plasma, using probes that bind to regions like LI, E2, E4, E5y, E6, and E7, and L2, forming a DNA scaffold for accurate sequencing and detection.
The method provides sensitive and specific detection of HPV 6 and HPV 11 DNA, enabling monitoring of disease severity, treatment response, and identifying pulmonary involvement, surpassing the limitations of traditional PCR methods by accurately distinguishing HPV DNA fragments from infected cells.
Smart Images

Figure IMGF000010_0001_TABLE 
Figure IMGF000011_0001_TABLE 
Figure IMGF000012_0001_TABLE
Abstract
Description
Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01METHODS OF DETECTING CIRCULATING CELL-FREE HPV 6 AND HPV 11 DNA IN LIQUID BIOPSIESSTATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0001] This invention was made in part with Government support under NIH Z01 Project Nos. ZIA BCO 12067-01 and ZIA BC012131. The Government has certain rights in this invention.FIELD OF THE INVENTION
[0002] The present invention relates to methods of detecting cell-free DNA of one or more of HPV 6 and HPV 11 in liquid biopsies. These methods may be used to detect conditions and diseases associated with chronic infection with HPV 6 or HPV 11, such as recurrent respiratory papillomatosis and anogenital condyloma.BACKGROUND OF THE INVENTION
[0003] Liquid biopsy has become an important diagnostic and monitoring tool for multiple different diseases. Previous data indicate the potential for monitoring circulating cell-free Human Papillomavirus (HPV) DNA from patients with HPV-associated cancer. Monitoring HPV DNA in the blood via liquid biopsy has been used to detect early cancer recurrence and guide treatment decisions. To date, liquid biopsy has had limited application to non-malignant, virus-associated conditions including recurrent respiratory papillomatosis (RRP).
[0004] Recurrent Respiratory Papillomatosis (RRP) is a rare neoplastic condition caused by chronic infection with HPV 6 or HPV 11. There are approximately 1,500 new cases of RRP diagnosed in the US each year. HPV-infected cells result in papillomatosis growths throughout the aerodigestive tract which can lead to dysphonia, dyspnea and, in some patients, fatal airway obstruction when disease is present in the lungs. Patients require repeat surgical debulking or laser ablation procedures to palliate symptoms. But latent viral infection persists resulting in continuous regrowth of papillomatosis disease. Repeated procedures to debulk the disease111050407.1 > JAtty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01expose patients to anesthetic and surgical risk, and emotional distress. In addition, it is estimated that the economic cost of RRP is 150 million dollars in the U.S. each year.
[0005] Surgery-sparing / replacing treatment options are being actively investigated. Adjuvant treatment strategies such as cidofovir and subcutaneous interferon have shown inconsistent clinical efficacy. Systemic treatment with cidofovir results in significant toxicities including nephrotoxicity and neutropenia, limiting its broad application. Programmed death (PD)-l pathway immune checkpoint blockade can reduce papilloma disease burden and enhance HPV- specific T-cell responses in some patients, but short courses of treatment are not curative, and the potential for autoimmune toxicity limits treatment duration. Preventative HPV vaccination is highly effective in preventing infection but fails to consistently provide clinical benefit to those already infected and diagnosed with RRP. Off-label use of systemic bevacizumab has demonstrated an ability to control disease burden and alleviate symptoms of RRP, but the response upon cessation of treatment does not last because the underlying chronic HPV infection is not addressed and continuous dosing can lead to toxicity.
[0006] A recent report demonstrated the use of quantitative real-time polymerase chain reaction (PCR) to measure circulating cell free HPV 11 DNA in a single patient with recurrent respiratory papillomatosis (RRP). Cell free HPV 11 DNA decreased to undetectable following excision of laryngeal papilloma. Although HPV cell free DNA (cfDNA) could be detected using PCR, the study was limited in that it could not be determined whether cfDNA could reliably detect papilloma recurrence and the PCR method may not have been sensitive as compared to other digital PCR approaches. The report also did not indicate that HPV cfDNA could be detected in patients without visible laryngeal papillomas. In addition, this approach did not determine whether the virus was intact like a complete virion, or if it came from an infected cell that then died. Accordingly, there is a need in the art for improved methods of detecting HPV cfDNA in liquid biopsies.SUMMARY OF THE INVENTION
[0007] Provided herein is a method of detecting Human papillomavirus (HPV) cell free DNA (cfDNA) in a liquid biopsy sample. The liquid biopsy sample may comprise peripheral blood, which may be plasma. The method may comprise providing cfDNA from a liquid biopsy sample from a subject; sequencing the cfDNA by performing a hybridization-based next generation111050407.1 _ 2 -Atty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01sequencing (NGS) panel on the cfDNA; and detecting the presence of a genomic sequence or fragment thereof of one or more of HPV 6 and HPV 11 from the NGS panel. The subject may have or be suspected of having a disease or condition caused by a chronic infection with HPV 6 or HPV 11. The subject may have recurrent respiratory laryngeal papillomatosis (RRP), which may be pulmonary, or anogenital condyloma. The subject may not have been diagnosed with a laryngeal papilloma. The subject may have a Derkay score >5, >3, or 0. The subject may have anogenital condyloma.
[0008] Performing the hybridization-based NGS panel may comprise contacting the cfDNA with a first set of probes that bind within regions of an HPV 6 genome comprising LI and at least one of or all of E2, E4, E5y, E6, E7, and L2 or a second set of probes that bind within regions of an HPV 11 genome comprising LI and at least one of or all of E2, E4, E5y, E6, E7, and L2.Performing the hybridization-based NGS panel may comprise contacting the cfDNA with the first set of probes and the second set of probes. The presence of genomic sequences or fragments thereof of one or more of HPV 6 and HPV 11 may be detected from the NGS panel. Each probe may have a length of about 60, 70, 80, 90, 100, 110, or 120 nucleotides.
[0009] Each of the first set of probes and the second set of probes may comprise n probes. Each of the n probes may bind to a different portion of the HPV 6 or HPV 11 genome, respectively, n may be >1, and each portion may be approximately the same length, n may be 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40. n may be 32.BRIEF DESCRIPTION OF THE DRAWINGS
[0010] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0011] FIG. 1 shows the amount of cfDNA in plasma from patients (pts) with different types of HPV-associated cancer, RRP pts, and healthy donors (HD).
[0012] FIG. 2 shows a schematic of the tiling-based detection method disclosed herein.
[0013] FIG. 3 A shows a picture (left) and CT scan (right) of a patient’s larynx with RRP.
[0014] FIG. 3B shows a schematic of detection of various regions across the HPV 11 genome using the detection method disclosed herein on cfDNA in the patient shown in FIG. 3A.
[0015] FIG. 4A shows a picture (left) and CT scan (right) of a patient’s larynx with RRP.111050407.1 _ 3 >Atty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01
[0016] FIG. 4B shows a schematic of detection of various regions across the HPV 11 genome using the detection method disclosed herein on cfDNA in the patient shown in FIG. 4A.DETAILED DESCRIPTION
[0017] The inventors have developed a method of detecting circulating cell-free HPV 6 and HPV 11 DNA in patients with chronic HPV 6 or HPV 11 infections, such as RRP. By using a hybridization-based next generation sequencing panel with coverage across the entire HPV 6 and HPV 11 genomes, the method is surprisingly better than known approaches, including the use of droplet digital PCR (ddPCR) limited to the LI region of an HPV genome and detection of HPV DNA in saliva. The method disclosed herein, unlike present methods, can measure fragments of HPV 6 and 11 genome that are specifically from infected cells.
[0018] Specifically, the method detects HPV DNA that comes from infected cells rather than intact virions that are intact in the peripheral blood that may not have infected a cell. The inventors discovered that most detected cfHPV DNA are the size of one nucleosome, suggesting that the virus came from HPV within a cell nucleus. When that cell dies, it sheds HPV DNA at the same fragment size as cfDNA. This means that the HPV DNA detected using the approach described herein is HPV DNA that has infected a cell, rather than a fully intact free virion.Moreover, the inventors have discovered that the HPV cfDNA fragments change over time, indicating that using traditional approaches relying on ddPCR with a single amplicon is unreliable when HPV DNA fragments are present but do not include any that can be amplified with the amplicon. The methods disclosed herein may be used in patients with RRP by guiding treatment decisions, determine the risk of patients developing pulmonary disease, stratify patients with extensive pulmonary disease and monitor for response to systemic therapies.1. Definitions
[0019] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.
[0020] For recitation of numeric ranges herein, each intervening number therebetween with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the111050407.1 - 4 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6,9, and 7.0 are explicitly contemplated.2. Methods of detecting Human papillomavirus cell free DNA
[0021] Provided herein is a method of detecting Human papillomavirus (HPV) cell free DNA (cfDNA) in a liquid biopsy sample. The subject may have or be suspected of having a disease or condition caused by chronic infection with one or more of HPV 6 and HPV 11. The disease may be recurrent respiratory papillomatosis (RRP) or anogenital condyloma. The RRP may be pulmonary. The subject may have RRP and may have a Derkay score of >5, >3, or 0. In one example, the subject may no longer have visible disease, which may be as measured on an endoscopic exam. The method may be used to determine whether the subject’s RRP was successfully treated or continues to have RRP. The method may be used to distinguish a solid pulmonary lesion from bulky laryngeal disease in a subject. The method may be used to identify the HPV genotype in a subject with RRP. The subject may be a human.
[0022] The method may comprise providing cfDNA from a liquid biopsy sample from the subject. The liquid biopsy sample may be a peripheral blood sample. The peripheral blood sample may be a plasma sample. The method may further comprise obtaining the liquid biopsy sample.
[0023] The method may comprise performing next generation sequencing (NGS) on one or more of HPV 6 and HPV 11 cfDNA from the liquid biopsy sample. The NGS may comprise a hybridization-based NGS panel. Methods of performing hybridization-based NGS panels are known in the art generally, but are not known specifically for use in detecting HPV in liquid biopsies. The hybridization-based NGS panel may comprise contacting the cfDNA with a collection of a plurality of probes.
[0024] The probes may bind within regions of an HPV 6 genome or HPV 11 genome. The regions may comprise LI and at least one of E2, E4, E5y, E6, E7, and L2. The regions may comprise all of LI, E2, E4, E5y, E6, E7, and L2. The probes may target a consensus sequence of the region of the HPV 6 or HPV 11 genome or a portion thereof. The HPV 6 genome may comprise the sequence of HPV6REF from PaVE: the papillomavirus episteme (pave.niaid.nih.gov / locus_viewer?seq_id=HPV6REF; GenBank Accession No. X00203). The HPV 11 genome may comprise the sequence of HPV11REF from PaVE111050407.1 _ 5 >Atty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01(pave.niaid.nih.gov / locus_viewer?seq_id=HPVl 1REF; GenBank Access No. M14119). The HPV 6 or HPV 11 genome may be approximately evenly divided (i.e., based on length) into portions, and the collection of probes may as a whole bind to all the portions. The portions may be representative of all the regions, and may fall within a region or across one or more regions. The one or more regions may span at least 50% of the HPV 6 or HPV 11 genome. In one example, the HPV 6 or HPV 11 genome is divided into n portions, where n is 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, or 40, or a range of two of the foregoing values. In one example, ti is 32. The collection of probes may comprise a plurality of probes, each of which binds to a different portion. The collection of probes may comprise multiple groups of probes, each of which binds to one of the portions of the HPV genome.
[0025] Each probe in the collection of probes may be a bridge probe and may form an interlocked 3D structure when bound to its target sequence. When a plurality of bridge probes, such as a group of probes described above, bind to a target sequence within the cfDNA, which may be a region as described above, an anchor probe may bind to the bridge probes, thereby forming a DNA scaffold with the target sequence. The anchor probe may be biotinylated.Capture beads, which may be coated with Streptavidin and which may further be magnetic, may bind the DNA scaffold. The capture beads may captured using a magnet to isolate target cfDNA bound to the capture beads. The isolated cfDNA may be sequenced. The presence of HPV 6 or HPV 11 sequences in the sequenced cfDNA may be indicative of HPV 6 or HPV 11 in the liquid biopsy. The amount of HPV 6 or HPV 11 cfDNA detected in the liquid biopsy may be compared to a respective control. The control may be the average amount of HPV 6 or HPV 11 cfDNA detected in liquid biopsies obtained from a population of human subjects who do not have an HPV infection, an active HPV infection, or who are confirmed not to have an HPV associated disease or condition such as RRP or anogenital condyloma. An increased amount of HPV 6 or HPV 11 cfDNA in the subject’s liquid biopsy compared to the control may be indicative of the presence of one or more of the HPV associated disease or condition, an active HPV infection, RRP, or anogenital condyloma.
[0026] Each probe may have the same length. The length may be 60-120 nucleotides. The length may be 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106,111050407.1 - 6 -Atty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 nucleotides or arange of two of the foregoing values.
[0027] In one example, a hybridization-based NGS panel is further performed to detect cfDNA of one or more of HPV 16 and HPV 18. The probes for targeting and sequencing HPV 16 and / or HPV 18 cfDNA may be based on the same design as described above in relation to HPV 6 and HPV 11. Detection of HPV 16 and / or HPV 18 cfDNA may serve as a control. The presence of HPV 6 or HPV 11 genome sequences in cfDNA from the liquid biopsy and the lack of HPV 16 and / or HPV 18 genome sequences may indicate the method specifically detects HPV 6 or HPV 11 cfDNA.
[0028] The methods disclosed herein may be used in a method of monitoring a subject’s response to a treatment for HPV 6 or HPV 11. The treatment may a first or second therapeutic disclosed herein below. The methods may be used in a method of determining additional treatment considerations for a disease caused by HPV 6 or HPV 11 in a subject. The methods may be used to determine severity of a disease caused by HPV 6 or HPV 11. The amount of cfDNA sufficient to detect HPV 6 or HPV 11 may be 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ng, or a range of two of the foregoing amounts.
[0029] The method may comprise detecting HPV 6 or 11 in a subject as described herein from a liquid biopsy obtained at a first time point and a liquid biopsy obtained at a second time point. The amount of HPV 6 or HPV 11 cfDNA may be compared between the first and second time point. A decrease or increase in the amount cfDNA in the second time point compared to the first time point may be indicative of decreased or increased severity, respectively, of the subject’s disease or condition.
[0030] The subject may have been administered a first therapeutic for an HPV 6 or HPV 11 infection, which may have been administered between the first and second time points. The amount of HPV DNA detected at the second time point may be compared to the amount at the first time point. An increase or no change in the amount of HPV DNA detected at the second time point compared to the first time point may be indicative of the ineffectiveness of the first therapeutic. The amount of the first therapeutic administered to the subject may be increased or a second therapeutic may be administered to the subject if the first therapeutic is not effective. A decrease in the amount of HPV DNA detected at the second time point as compared to the first may be indicative of the efficacy of the first therapeutic. The amount of the first therapeutic111050407.1 . y .Atty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01administered to the subject may be maintained or decreased. The first therapeutic and second therapeutic may independently be an immunotherapeutic (e.g., an HPV-specific immunotherapeutic), bevacizumab, cidovir, interferon-alpha, indole-3-carbinol, an HPV vaccine such as Gardasil, a PD-1 inhibitor (e.g., nivolumab or pembrolizumab), photodynamic therapy, a T-cell receptor (TCR) T-cell therapy that targets HPV 6 or HPV 11, or tumor or papilloma infiltrating lymphocyte therapy. The first therapeutic and second therapeutic may be different. The second therapeutic may be combined with the first therapeutic.
[0031] The methods disclosed herein may also be used to identify whether a subject has one or more of HPV 6 or HPV 11. A subject suspected of having anogenital condyloma may have multiple HPV genotypes, which may be determined by using a swab. For example, the swab may be positive for HPV 6, 11, 16 and 18. The method may identify the causative HPV genotype as compared to external colonization. Identification of HPV 6 or HPV 11 in the subject may be used to determine the subject’ s eligibility for a TCR T-cell therapy specific to HPV 6 or HPV 11.
[0032] The methods disclosed herein may be used to detect juvenile-onset RRP in a subject, who may be a baby. The juvenile-onset RRP may have been acquired through vertical transmission (that is, the baby acquired it from their mother following vaginal delivery when the mother had an active HPV 6 or HPV 11 disease such as genital wart outbreak). The method may be used to monitor the subject’s RRP status.
[0033] The methods disclosed herein may be used to detect pulmonary RRP by determining the number of unique HPV 6 or HPV 11 cfDNA fragments found in the liquid biopsy. The liquid biopsy sample may be highly positive, and the subject may exhibit little or no laryngeal disease as seen on endoscopic exam, such that the amount of circulating cell-free (ccf) HPV DNA may be coming from a pulmonary lesion. If the subject has small to minimal laryngeal disease that is found to have a high number of ccfHPV DNA fragments, then the subject may have pulmonary disease. On the other hand, if the subject has small to minimal laryngeal disease that is found to have a small number of ccfHPV DNA fragments, then the subject may not have pulmonary disease. The methods may also be used to determine whether an HPV cfDNA fragment originated from an infected cell or an intact virion.
[0034] The methods disclosed herein may be used to determine the severity of the subject’s RRP. Detection of HPV 11 cfDNA, as opposed to HPV 6 cfDNA, may indicate that the subject’s HPV associated disease or condition is more aggressive. The methods may also be used to detect111050407.1 - 8 -Atty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01pulmonary RRP in the subject. An increased quantity of unique cfDNA fragments may be associated with increased severity of the subject’s disease or condition, and may be indicative of the presence of pulmonary disease.
[0035] Provided herein are methods of treating a subject determined to have the HPV 6 or HPV 11 associated disease or condition, who may be treated using a first therapeutic disclosed herein. The method may comprise administering the first therapeutic to the subject, who may have been determined to have the HPV 6 or HPV 11 associated disease or condition. The method may further comprise performing one or more of the steps disclosed herein for detecting HPV 6 or HPV 11 in a liquid biopsy from the subject. Provided herein are use of the first therapeutic in the manufacture of a medicament for treating an HPV 6 or HPV 11 associated disease or condition caused by active HPV 6 or HPV 11, or the first therapeutic for use in treating the HPV 6 or HPV 11 associated disease or condition.
[0036] The present invention has multiple aspects, illustrated by the following non-limiting examples.Example 1Detecting HPV 6 and HPV 11 cfDNA in Liquid Biopsies
[0037] To determine HPV 6 / 11 DNA can be detected in liquid biopsies, DNA was extracted from laryngeal papilloma from patients with RRP. A custom primer probe set was designed for performing a next-generation sequence panel using the consensus DNA sequence for each of the HPV 6, 11, 16 and 18 genomes, and a pull-down DNA technology was used to improve coverage. A set of primer probes was designed in which each probe targeted a unique portion of the HPV genome defined by evenly dividing the genome into 32 portions. The probes spanned the LI, E2, E4, E5y, E6, E7, and L2 regions of each HPV genome. The probes were high affinity short oligonucleotides, each of equal length in the range of 80-120 nucleotides.
[0038] Initial studies were performed on papilloma tissue to demonstrate that the primer probe set was working appropriately. As demonstrated in the table below, the two papilloma specimens from patients with HPV6 disease showed significantly high reads for HPV6 probes (1-3 million) while the three papilloma specimens from patients with HPV11 disease showed significantly high reads for HPV11 probes (3-9 million). PBMC from patients with HPV+ cancer was used as a negative control and demonstrated either 0-1 reads for HPV6 / 11 likely representing intrinsic111050407.1 - 9 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01background of the assay. In the table below, the top row indicates samples, with the far three right columns being blood cells. The HPV serotype is indicated in far-left column. Numbers in rows 3-6 indicate read counts.Table 1 Detection of HPV 6 and 11 DNA in papillomatarget GC% 8A_R 10A RR 19A RRP 22A RRP 30B RRP Pt4 PB Pt5 PB Ptl2 PB RP_S1 P_S2 a_S3 _S4 _S5 MC_S6 MC_S7 MC_S8 HPV6 1IPV6 HPV11 HPV11 HPV11 HPV16 HPV16 HPV16 I IPV6 19581 3527237 2658 308 1721 0 0 010HPV11 67 55 5615137 3025352 9410781 1 1 1 HPV 16 0 0 0 0 0 20 2 1 HPV18 0 0 0 0 0 0 0 0
[0039] Next, experiments were conducted to determine whether HPV 6 and 11 DNA could be detected in the peripheral blood of patients with RRP. Previous studies have used PCR-based methods to amplify one or two specific regions of the viral genome. However, fixed primer locations can limit detection of viral DNA due to the small amount of ccfHPV DNA fragments in patients with RRP. To address this limitation, a hybridization-based HPV NGS panel targeting four different subtypes (HPV 6, 11, 16 and 18), covering the entire HPV genome, was used. In the table below, the top row indicates samples, the second row indicates HPV type, and rows 4-7 indicate read count for the specific HPV probe (that is, 6, 11, 16 and 18). cfDNA indicates samples of cell free HPV 6 / 11 DNA, and gDNA indicates samples of HPV DNA extracted from papilloma (positive control).111050407.1 - 10 -Table 2 Detection of circulating cell-free HPV 6 and 11 DNA in plasmacfDNA gDNAtarget GC% hpv lO hpv lO hpv_19 hpv_19 hpv_22 hpv_30 hpv_30 hpv_5_ hpv_5_ hpv_8_ hpv_g_10 hpv g 19 hpv g 22 hpv g 30 hp'_g_ hpv g 8A 0039 0114 0119 0284 0133 0179 0297 017 301 028 ARRP ARRP ARRP BRRP 5ARR RRP P HPV 6 6 11 11 11 11 11 6 6 6 6 11 11 11 6 6 Taoti 1.5 16.8 13.5 1.4 0.1 0.3 1.2 04 5 0.2 1.4 12.2 0.8 1.5 1 4 ReadsHPV6 14 12 18 10 11 23 24 27 15 19 1129708 4790 67 223 763428 3261089 HPV11 0 1 10 1 0 3 3 1 0 1 20 8049430 595966 1126546 12 55HPV16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0HPV18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01
[0040] In the first experiment, cell free DNA was extracted from plasma specimens collected from three patients with HPV 6-driven RRP and three patients with HPV 11 -driven RRP. As demonstrated in the table below, HPV 6 / 11 DNA was detected in all 10 specimens with no reads for HPV 16 or 18. This includes patients with significantly low levels of disease as measured by Derkay score (table below). This suggests that the sensitivity of this approach may actually be better compared to measurements of localized techniques including saliva.Table 3 Derkay score at the time of plasma specimen collection Patient HPV 6 or 11 Sample number Derkay score5 6 hpv 5 0017 195 6 hpv 5 0301 08 6 hpv 8 0028 3110 6 hpv 10 0039 1210 6 hpv 10 0114 119 11 hpv 19 0119 1619 11 hpv 19 0284 222 11 hpv 22 0133 2430 11 hpv 30 0179 1530 11 hpv 30 0297 3
[0041] Next, specimens from patients with minimal laryngeal disease burden but with a known amount of pulmonary disease were tested to see whether the amount of circulating cfDNA from HPV 6 / 11 correlated to the amount of pulmonary disease. Pulmonary lesions may appear as cysts, nodules or solid or cavitary masses. Solid masses are more likely to cause post-obstructive pneumonia and may be more likely to undergo malignant transformation. As demonstrated in the table below, all patients tested had minimal laryngeal disease at the time of plasma collection (Derkay score of 0-3).Table 4Sample ID # PL 0018 PL 0022 PL 0025HPV genotype of 6 11 6papillomaDescription of 5 mm cystic lesion 37 mm solid lesion 16 mm cystic lesion pulmonary diseaseAnatomic Derkay score 3 0 3HPV 6 (primer read 3 6 11count in cfDNA)HPV 11 (primer read 1 458 0count in cfDNA)HPV 16 (primer read 0 0 0count in cfDNA)111050407.1 - 12 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01HPV 18 (primer read 0 0 0count in cfDNA)
[0042] Surprisingly, the patient with a Derkay score of 0 was found to have the highest level of cfHPV DNA in plasma (read count of 458). Additionally, the probes amplified more than 25 regions of the HPV 11 genome. In contrast, patients with cystic lung lesions had significantly less HPV cfDNA in the plasma (read count of 3 and 11). It is hypothesized that the very high level of HPV 11 DNA in the patient with no laryngeal disease came from the 3.7 cm solid pulmonary lesion. This is in contrast to the two other patients (PL 0018 and PL 0025) who had much smaller cystic lesions. Therefore, it is possible that the level of cfHPV DNA in circulation is based on the nature of the pulmonary disease (i.e., size and type of pulmonary lesion(s)).
[0043] In contrast, a droplet digital PCR using primers targeting the LI region of HPV 6 or HPV 11 was unable to detect cfDNA.Conclusions
[0044] This data confirms that the method described herein effectively detects circulating cell- free HPV 6 / 11 DNA from liquid biopsies of patients with RRP, a chronic HPV 6 / 11 -driven disorder. This assay could potentially be used clinically to monitor for response to treatment, to guide additional treatment considerations, and potentially be used as a marker of disease severity, especially in the setting of pulmonary disease. The assay could also potentially be utilized in other conditions driven by chronic HPV 6 / 11 such as anogenital condyloma, which is significantly more common than RRP.Example 2Use of liquid biopsy to detect cell-free HPV 6 and HPV 11 DNA in patients with recurring respiratory papillomatosis
[0045] Timely diagnosis of recurrent respiratory papillomatosis (RRP) remains a challenge due to rarity of the condition and non-specific symptoms. Frequent misdiagnoses lead to treatment delays and inappropriate medical interventions. Oral and respiratory testing for HPV 6 / 11 is not effective in aiding diagnosis due to high levels of HPV colonization in the general population. A prior study demonstrated the ability to detect cell-free (cf)HPVl 1 DNA in circulation of a patient with bulky laryngeal disease but not minimal disease that occurred following surgery. This111050407.1 - 13 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01example demonstrates successful development of a blood-based liquid biopsy assay sensitive enough to measure cfHPV6 / l 1 DNA irrespective of laryngeal disease burden.
[0046] Ten archived plasma specimens from 9 adult patients with RRP enrolled in a clinical trial of systemic bevacizumab-bvzr (NCT05797246) were studied. Plasma cfDNA was extracted, hybridized to a custom capture kit with tiling probes encompassing the entire HPV 6 and 11 genomes, and sequenced.
[0047] Patients had a median Derkay score of 3 (range 0-16) including 3 patients with Derkay 0. Four patients had HPV6-related disease and five had HPV11. cfHPV DNA was identified in 6 of 10 (60%) specimens and 2 of 3 patients with Derkay 0. All HPV genotypes identified by liquid biopsy matched those of corresponding papilloma. Most positive cases identified only a single unique cfHPV DNA fragment. Interestingly, 378 unique cfHPVl 1 DNA fragments from across the genome were identified in a patient with Derkay 0. This patient had a 3.6 x 2.4-centimeter solid pulmonary nodule on chest computed tomography (CT) scan which likely contributed to the large quantities of cfHPVl 1 DNA.
[0048] cfHPV DNA was detected in most patients including those with no visible laryngeal disease. Large quantities of cfHPV DNA were found in an individual with a solid pulmonary nodule, highlighting the potential of this approach in identifying pulmonary disease.Example 3Use of tiling probes encompassing the entire HPV 6 and HPV 11 genomes is superior to a single, droplet digital PCR amplicon in detecting HPV cfDNA in liquid biopsies
[0049] This examples show that the methods disclosed herein work much better than a standard single, droplet digital PCR (ddPCR) amplicon for detecting HPV cfDNA in RRP patients. cfDNA was detected in liquid biopsies from patients with advanced HPV-associated cancer, RRP patients, and healthy donors. It was observed that RRP patients had higher cfDNA levels than healthy donors. cfDNA HPV, as shown in Tables 5-7 below.Table 5 Advanced HPV Patients18C0056 cancer time Cancer cfDNA yield per ml patients of plasma (ng)1 DI H&N 4.61 D15 H&N 17.81 D41 H&N 137.13 DI Cervical 6.4111050407.1 - 14 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-013 D14 Cervical 3.86 DI Cervical 9.26 D14 Cervical 18.96 D40 Cervical 25.18 DI Cervical 6.18 D14 Cervical 8.88 D42 Cervical 9.453 DI Anal 18.253 D15 Anal 8.153 D42 Anal 11.957 DI Cervical 29.557 D15 Cervical 21.557 D41 Cervical 14.8Median of 149 9.6samplesAverage of 149 28.2samplesTable 6 RRP PatientsRRP samples cfDNA yield per ml of plasma (ng)1 3.32 3.53 3.84 4.35 3.26 2.47 2.18 2.7median 3.3average 3.2Table 7 Healthy DonorsHealthy donor cfDNA yield per ml of plasma (ng)W092122011126 2.4W092122011239 1.3W092122011362 2.4W092122015403 0.8W092123010148 1.7W092122014557 1.6W092122015621 2.4Median of 7 HD 1.7Average of 7 HD 1.8111050407.1 - 15 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01
[0050] The cfDNA yield per mL of plasma in each of these groups is shown in FIG. 1.
[0051] Using a single, droplet digital PCR amplicon was ineffective in detecting cfDNA from HPV 6 and HPV 11 in liquid biopsies from patients with RRP, as shown in Tables 8-13. Plasma from RRP patients was tested in a blinded fashion (it was not known if these patients were HPV6 orHPVll positive).Table 8Control HPV DNA HPV6 Cone RPP30 Cone Ratiosamples type amount (copies / pL) (copies / pL) HPV6 / RPP30(Pg)*g6-l 6 200 1,735.82 11.07 156.8*g6-2 6 200 55.92 0.95 58.86*g6-3 6 200 45.27 3.92 11.55CaSki 16 1000 0 8.7 0C33a negative 1000 0 5.25 0*Genomic DNA from RRP lesionTable 9Healthy Donor HPV DNA HPV6 Cone RPP30 Cone Ratio plasma type amount (copies / pL) (copies / pL) HPV6 / RPP30(Pg)HD4 plasma NA 200 0 33.28 0HD5 plasma NA 200 0 14.19 0HD6 plasma NA 200 0 170.31 0HD7 plasma NA 200 0 26.57 0HD4 plasma NA 330 0 49.88 0HD5 plasma NA 500 0 31.53 0HD6 plasma NA 340 0 270.7 0HD7 plasma NA 500 0 63.31 0126 plasma NA 500 0 622.81 0362 plasma NA 500 0 243.3 0239 plasma NA 350 No Call No Call - 126 plasma NA 200 0 425.3 0111050407.1 - 16 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01362 plasma NA 200 0 110.85 0Table 10RRP Patient HPV DNA HPV6 Cone RPP30 Cone Ratio plasma type amount (copies / pL) (copies / pL) HPV6 / RPP30(Pg)ptl pre unknown 200 No Call No Call - ptl post unknown 200 No Call No Call - pt3 pre unknown 200 0 10.75 0pt3 post unknown 200 0 9.29 0pt5 pre unknown 200 0 11.37 0pt5 post unknown 200 0 12.13 0pt8 pre unknown 200 0.07 6.94 0.01 pt8 post unknown 200 0 11.17 0ptl pre unknown 500 0 17.57 0ptl post unknown 500 0 27.95 0pt3 pre unknown 500 0 20.28 0pt3 post unknown 500 0 21.97 0pt5 pre unknown 500 0 8.86 0pt5 post unknown 500 0 12.21 0pt8 pre unknown 450 0 1.48 0pt8 post unknown 500 0 20.4 0Table 11DNAControl HPV HP11 Cone RPP30 Cone Ratioamountsample type (copies / pL) (copies / pL) HPV11 / RPP30(Pg)*gll-l 11 200 54.50 2.10 25.95*gll-2 11 200 23.69 1.23 19.26*gll-3 11 200 468.88 6.46 72.58CaSki 16 1000 0.06 8.55 0.01C33a negative 1000 0.00 5.01 0.00*Genomic DNA from RRP lesionTable 12Healthy HPV DNA HP11 RPP30 Cone Ratiodonor type amount Conc(copies / pL) (copies / pL) HPV11 / RPP30plasma (Pg) _111050407.1 - 17 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01HD4 NA 200 0 34.46 0plasmaHD5 NA 200 0 15.38 0plasmaHD6 NA 200 0 167.22 0plasmaHD7 NA 200 0 23.5 0plasmaHD4 NA 330 0 56.47 0plasmaHD5 NA 500 0 29.59 0plasmaHD6 NA 340 0 276.95 0plasmaHD7 NA 500 0 58.61 0plasma126 NA 500 0 1,821.45 0plasma362 NA 500 0 345.76 0plasma239 NA 127 0 223.48 0plasma126 NA 200 0 392.42 0plasma362 NA 200 0 110.41 0plasmaTable 13RRP Patient HPV DNA HPV11 RPP30 Ratio plasma type amount Conc(copies / pL) Conc(copies / pL) HPV11 / RPP30(Pg)ptl pre unknown 200 0 12.76 0ptl post unknown 200 0 13.23 0pt3 pre unknown 200 0 13.1 0pt3 post unknown 200 0 8.28 0111050407.1 - 18 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01pt5 pre unknown 200 0 19.08 0pt5 post unknown 200 0 13.74 0pt8 pre unknown 200 0 8.57 0pt8 post unknown 200 0 11.36 0ptl pre unknown 500 0 22.65 0ptl post unknown 500 0 27.87 0pt3 pre unknown 500 0 20.93 0pt3 post unknown 500 0 14.26 0pt5 pre unknown 500 0 11.87 0pt5 post unknown 500 0 17.29 0pt8 pre unknown 450 0 1.94 0pt8 post unknown 500 0 27.3 0
[0052] Single probe ddPCR amplifying HPV LI 6509-6667 failed to identify circulating cfHPV 6 / 11 DNA. Due to the scarcity of circulating cell-free HPV 6 / 11 DNA in blood, an ultrasensitive test was needed to find rare circulating DNA fragments. Accordingly, a primer-probe set with “pull down” technology that covers the entire HPV6 and HPV11 genome was developed.
[0053] Tiling probes across HPV6 and HPV11 genomes were designed. The 7 kb genome was divided into 36 different target regions to increase sensitivity. It was estimated that this approach would increase the sensitivity by at least 36-fold comparing to ddPCR, which only targets one region in HPV LI gene. The traditional ddPCR assay might have even lower sensitivity because both forward and reverse primers must be within the small randomly sheared cfDNA fragment (168 bp long). If the random shearing occurs a little upstream or downstream, then ddPCR will111050407.1 - 19 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01not be able to detect the viral DNA, in contrast to the tiling-based methods disclosed herein (FIG. 2).
[0054] The method disclosed herein was tested on a patient with a Derkay score of 0 and no visible papilloma in their larynx (FIG. 3 A). The patient had a high quantity of cfHPVl 1 in their blood (FIG. 3B). The method was also tested on the same patient at a later time point, when they had a Derkay score of 0 and no visible papilloma in their larynx (FIG. 4A). The patient also had a high quantity of cfHPV 11 in their blood (FIG. 4B). FIG. 4B illustrates why using the standard HPV 11 LI ddPCR amplicon 6509-6667 would not have detected any HPV in this patient. The table below shows that the method specifically detected HPV 11 in the patient’s sample.Table 14reference ref length reads mapped_S4HPV6 7996 14HPV11 7931 9618 (9806)HPV16 7906 58HPV18 7857 2unmapped / 3,085,144
[0055] The methods disclosed herein were used to detect HPV 11 cfDNA in plasma from RRP patients. The results of the test and characteristics of each patient are shown in the table below. Bev patient 1 had 0.4 cm nodules, patient 2 had a 3.5 cm nodule, patient 4 had cystic lung disease, patient 5 had no lung disease, patient 6 had cystic lung disease and one nodule that was 1.1 x 1.0, patient 8 had no lung disease, patient 11 had no lung disease, Patient 12 had a small grouping of subcentimeter nodules in RLL, and patient 17 had a 0.2 cm subpleural nodule.Table 15Patient HPV plasma qubit cDNA cfDNA total total post-tx Derkay Testing type volume ng / uL % screen cDNA cfDNA Result used tape volumemL pg / uL uLBev patient 1 6 2 0.55 89.46 262 45 11.8 3 HPV6+ Bev patient 2 11 1.7 0.4 60.85 48 45 2.2 0 HPV 11+++++ Bev patient 4 6 2 078 94 87 568 45 256 3 negative Bev patient 5 11 1.1 1.38 96.21 1060 45 47.7 3 HPV11+ Bev patient 5 11 2 0.53 93.33 269 45 12.1 2 HPV11+ Bev patient 6 11 1.8 0.57 90.55 217 45 9.8 0 HPV11+ Bev patient 8 11 1 9 044 92 57 118 45 5 3 3 negative Bev patient 11 6 2 0.64 88.88 189 45 8.5 1 negative Bev patient 12 6 2 1.26 93.99 882 45 39.7 0 negativeBev patient 17 11 2 0.52 82.83 73.6 45 3.3 16 HPV11+111050407.1 - 20 -Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01
[0056] The results show that the methods disclosed herein are capable of detecting HPV 6 and HPV 11 cfDNA in liquid biopsies, even in RRP patients with a Derkay score of 0.111050407.1 - 21 -
Claims
Aty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01CLAIMSWhat is claimed is:
1. A method of detecting Human papillomavirus (HPV) cell free DNA (cfDNA) in a liquid biopsy sample, comprising(a) sequencing the cfDNA from a liquid biopsy sample from a subject by performing a hybridization-based next generation sequencing (NGS) panel on the cfDNA; and(b) detecting the presence of a genomic sequence or fragment thereof of one or more of HPV 6 and HPV 11 from the NGS panel.
2. The method of claim 1, wherein the subject has or is suspected of having a disease or condition caused by a chronic infection with HPV 6 or HPV 11.
3. The method of claim 2, wherein the disease or condition is recurrent respiratory papillomatosis (RRP) or anogenital condyloma.
4. The method of claim 3, wherein the subject has RRP.
5. The method of claim 4, wherein the subject has not been diagnosed with a laryngeal papilloma.
6. The method of claim 5, wherein the subject has a Derkay score >5.
7. The method of claim 5, wherein the subject has a Derkay score of >3.
8. The method of claim 5, wherein the subject has a Derkay score of 0.
9. The method of claim 2, wherein the subject has anogenital condyloma.
10. The method of claim 1, wherein performing the hybridization-based NGS panel comprises contacting the cfDNA with a first set of probes that bind within regions of an HPV 6 genome comprising LI and at least one of E2, E4, E5y, E6, E7, and L2 or a second set of probesAty. Docket No. 060734-892251Client Ref.: E-019-2025-0-PC-01that bind within regions of an HPV 11 genome comprising LI and at least one of E2, E4, E5y, E6, E7, and L2.
11. The method of claim 10, wherein performing the hybridization-based NGS panel comprises contacting the cfDNA with the first set of probes that bind within regions of an HPV 6 genome comprising LI and at least one of E2, E4, E5y, E6, E7, and L2 and the second set of probes that bind within regions of an HPV 11 genome comprising LI and at least one of E2, E4, E5y, E6, E7, and L2; and wherein the presence of genomic sequences or fragments thereof of HPV 6 and HPV 11 are detected from the NGS panel.
12. The method of claim 10 or 11, wherein each probe has a length of about 60, 80, 100, or 120 nucleotides.
13. The method of claim 10 or 11, wherein each of the first set of probes and the second set of probes comprises n probes, wherein each of the n probes binds to a different portion of the HPV 6 or HPV 11 genome, respectively, wherein n is >1, and wherein each portion is approximately the same length.
14. The method of claim 13, wherein n is 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40.
15. The method of claim 14, wherein n is 32.
16. The method of claim 1 wherein the liquid biopsy sample comprises peripheral blood.
17. The method of claim 16, wherein the peripheral blood is plasma.
